Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer

This study is testing whether adding a targeted radiation technique to the liver (called stereotactic body radiation therapy, or SBRT) to standard immunotherapy treatment improves outcomes in people with non-small cell lung cancer (NSCLC) that has spread to the liver. The radiation is thought to potentially stimulate the immune system to attack the cancer more broadly. **You may be eligible if:** - You are at least 18 years old - You have confirmed NSCLC with liver metastases - You are eligible for immune checkpoint inhibitor therapy - Your cancer is measurable on scans (RECIST criteria) - Your general health and organ function are adequate (ECOG 0–2) **You may NOT be eligible if:** - Your liver tumor cannot be targeted safely with radiation - You have cirrhosis or end-stage liver disease - You have another active invasive cancer (diagnosed within the past year) - You have active tuberculosis, hepatitis B, or hepatitis C - You have an autoimmune disease requiring systemic treatment - You received a live vaccine within the past 30 days Talk to your doctor to see if this trial is right for you.